VCRE (Vicore Pharma Holding AB) Short-term investments


VCRE Vicore Pharma Holding AB VCRE
13 GF Score
Price $15.03
! 5 Warning Signs
View Full Analysis

What is Vicore Pharma Holding AB Short-term investments?

Short-term investments only applies to insurance companies.

VCRE
13GF Score
Vicore Pharma Holding AB VCRE
Short-term investments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vicore Pharma Holding AB Business Description

Comparable Companies
Other Exchanges VICO:Sweden6Y4:Germany
Address Kornhamnstorg 53, Stockholm, SWE, 111 27
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
13GF Score

Get the complete analysis for VCRE

Short-term investments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.03
Price